PRISCILLA SCHNUR: Open Payments
NPI 1396392353 · NOBLESVILLE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,604 in 91 payments from 15 companies in 2025. Trend: 2023 $469 · 2024 $678 · 2025 $1,604
Food & beverage: $1,604
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 6 | $219 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $213 |
| Otsuka America Pharmaceutical, Inc. | 14 | $206 |
| Neurocrine BioSciences, Inc. | 14 | $188 |
| E.R. Squibb & Sons, L.L.C. | 4 | $177 |
| ABBVIE INC. | 16 | $173 |
| Axsome Therapeutics, Inc. | 5 | $106 |
| Teva Pharmaceuticals USA, Inc. | 5 | $78 |
| Lundbeck LLC | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $52 |
Products named: REXULTI, CAPLYTA, INGREZZA, COBENFY, VRAYLAR, FANAPT, Auvelity, HETLIOZ.
Industry payments across IN — which companies pay providers there.
